Prosoma was started in 2018 and is an early trailblazer in digital healthcare. The company is on a mission to revolutionise oncology treatment with its flagship product, Living Well Plus, which stands out as the only digital healthcare solution that provides clinically validated behavioural and psychological support tailored specifically for cancer patients. Through a unique blend of comprehensive virtual care, CE-approved mobile applications, and personalised tele-coaching, Living Well therapy program has been shown to reduce anxiety, stress, and depression in oncology patients by 25-50%.
“Our goal is to enhance the quality of life for cancer patients while simultaneously decreasing the financial burden on payers,” stated Marek Ostrowski, CEO of Prosoma. “We are truly grateful for the trust our investors have placed in us during these challenging market conditions. This funding will enable us to scale our operations in the DACH region and significantly expand our outreach efforts in the United States.”
Prosoma’s innovative approach to oncology care is not just about treating the disease; it’s about enhancing the overall experience and outcomes for patients living with cancer.
“Cancer treatment is often a long and challenging process that can span many years, making it essential to focus not only on survival but also on the quality of life for patients” stated Dr. Philipp Rösler, member of the Prosoma advisory board and former German Minister of Health. “In this context, remote patient monitoring and integrated support systems are becoming increasingly vital. They empower patients to manage their health more effectively and provide healthcare professionals with critical insights into patient well-being.”
"Prosoma is addressing a critical unmet need in oncology care," said Gergely Iváncsics, partner at Impact Ventures. "Their focus on improving both the mental health and well-being of patients aligns perfectly with our investment thesis. We are excited to partner with Prosoma as they scale their innovative solutions and transform the future of oncology care."
Throughout 2024, Prosoma achieved remarkable results by assisting over 2,573 patients, with sales reaching €1 million, fueled by collaborations with more than 30 strategic partners throughout the DACH area. It has also secured key strategic partnerships in the US, including one of the world’s best cancer centres, Cedars Sinai.
The company now plans to broaden its offerings beyond emotional support, aiming to provide a comprehensive suite of services, including nutrition and coaching, to holistically address the needs of cancer patients.
Navigating a cancer diagnosis can be an emotionally taxing journey, often resulting in distress that adversely affects patients’ ability to manage their condition. Studies indicate that rates of major depressive disorder can be up to three times higher among cancer patients compared to the general population. Given the evidence that poor mental health can significantly impair treatment outcomes, the need for effective support systems has never been more critical.
The capital raised will be allocated towards expanding Prosoma’s operations within the DACH market and growing the sales team to support increased demand. The company is also preparing to establish a robust presence in the U.S. market, which includes pursuing new reimbursement pathways.
For additional information about Prosoma and its commitment to enhancing cancer care, please visit www.prosoma.com.
###
About Prosoma:
Prosoma is dedicated to revolutionising oncology care by enhancing the quality of life for cancer patients through innovative mental health and nutrition programs. Our approach aims to significantly reduce treatment costs while providing essential emotional support to those facing cancer.
Media Contact:
Emanuela Kufel, Prosoma Co-founder
Email: ema@prosoma.com
Phone: +44 7515436458